PT - JOURNAL ARTICLE AU - Biswas, Subarna AU - Hilser, James R. AU - Woodward, Nicholas C. AU - Wang, Zeneng AU - Gukasyan, Janet AU - Nemet, Ina AU - Schwartzman, William S. AU - Huang, Pin AU - Han, Yi AU - Fouladian, Zachary AU - Charugundla, Sarada AU - Spencer, Neal J. AU - Pan, Calvin AU - Tang, W.H. Wilson AU - Lusis, Aldons J. AU - Hazen, Stanley L. AU - Hartiala, Jaana A. AU - Allayee, Hooman TI - Effect of Genetic and Dietary Perturbation of Glycine Metabolism on Atherosclerosis in Humans and Mice AID - 10.1101/2023.12.08.23299748 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.08.23299748 4099 - http://medrxiv.org/content/early/2023/12/11/2023.12.08.23299748.short 4100 - http://medrxiv.org/content/early/2023/12/11/2023.12.08.23299748.full AB - Objective Epidemiological and genetic studies have reported inverse associations between circulating glycine levels and risk of coronary artery disease (CAD). However, these findings have not been consistently observed in all studies. We sought to evaluate the causal relationship between circulating glycine levels and atherosclerosis using large-scale genetic analyses in humans and dietary supplementation experiments in mice.Methods Serum glycine levels were evaluated for association with prevalent and incident CAD in the UK Biobank. A multi-ancestry genome-wide association study (GWAS) meta-analysis was carried out to identify genetic determinants for circulating glycine levels, which were then used to evaluate the causal relationship between glycine and risk of CAD by Mendelian randomization (MR). A glycine feeding study was carried out with atherosclerosis-prone apolipoprotein E deficient (ApoE−/−) mice to determine the effects of increased circulating glycine levels on amino acid metabolism, metabolic traits, and aortic lesion formation.Results Among 105,718 subjects from the UK Biobank, elevated serum glycine levels were associated with significantly reduced risk of prevalent CAD (Quintile 5 vs. Quintile 1 OR=0.76, 95% CI 0.67-0.87; P<0.0001) and incident CAD (Quintile 5 vs. Quintile 1 HR=0.70, 95% CI 0.65-0.77; P<0.0001) in models adjusted for age, sex, ethnicity, anti-hypertensive and lipid-lowering medications, blood pressure, kidney function, and diabetes. A meta-analysis of 13 GWAS datasets (total n=230,947) identified 61 loci for circulating glycine levels, of which 26 were novel. MR analyses provided modest evidence that genetically elevated glycine levels were causally associated with reduced systolic blood pressure and risk of type 2 diabetes, but did provide evidence for an association with risk of CAD. Furthermore, glycine-supplementation in ApoE−/− mice did not alter cardiometabolic traits, inflammatory biomarkers, or development of atherosclerotic lesions.Conclusions Circulating glycine levels were inversely associated with risk of prevalent and incident CAD in a large population-based cohort. While substantially expanding the genetic architecture of circulating glycine levels, MR analyses and in vivo feeding studies in humans and mice, respectively, did not provide evidence that the clinical association of this amino acid with CAD represents a causal relationship, despite being associated with two correlated risk factors.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported, in part, by NIH Grants R01HL133169 and R01HL148110. The Gene-Bank study was supported in part by NIH grants P01HL098055, P01HL076491, and R01HL103931. Mass Spectrometry instrumentation used for the GeneBank study was housed in a facility supported in part through a Shimadzu Center of Excellence award. We gratefully acknowledge the UK Biobank Resource for providing access to their data under Application Number 33307. The sponsors had no role in study design, data collection and analysis, decision to pub-lish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The GeneBank study has been approved by the Institutional Review Board of the Cleveland Clinic and the present analyses were approved by the Institutional Review Board of USC Keck School of Medicine. Animal studies were performed with approval and in accordance with the guidelines of the Institutional Animal Research Committees of the University of Southern California.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesIndividual level data used in the present study are available upon application to the UK Biobank (https://www.ukbiobank.ac.uk/). Summary statistics from the meta-analysis for glycine levels will be posted to a public repository. Summary statistics for glycine levels from all other datasets used in the present study are available through their respective publications. All other relevant data are available upon request from the authors. https://pheweb.org/metsim-metab/ https://jmorp.megabank.tohoku.ac.jp https://www.ebi.ac.uk/gwas/